CN113501848A - 钌配合物纳米级颗粒及其制备方法和应用以及抗肿瘤药物 - Google Patents
钌配合物纳米级颗粒及其制备方法和应用以及抗肿瘤药物 Download PDFInfo
- Publication number
- CN113501848A CN113501848A CN202111053500.8A CN202111053500A CN113501848A CN 113501848 A CN113501848 A CN 113501848A CN 202111053500 A CN202111053500 A CN 202111053500A CN 113501848 A CN113501848 A CN 113501848A
- Authority
- CN
- China
- Prior art keywords
- drug
- ruthenium complex
- tumor
- tumor drug
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012327 Ruthenium complex Substances 0.000 title claims abstract description 73
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 55
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 22
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 144
- 229940079593 drug Drugs 0.000 claims abstract description 120
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 93
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 51
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 19
- 125000003172 aldehyde group Chemical group 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 238000010992 reflux Methods 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000007795 chemical reaction product Substances 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 229910052751 metal Inorganic materials 0.000 claims description 14
- 239000002184 metal Substances 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- -1 amino, carboxyl Chemical group 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 239000000460 chlorine Substances 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 229940126062 Compound A Drugs 0.000 claims description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000001338 self-assembly Methods 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- FZHCFNGSGGGXEH-UHFFFAOYSA-N ruthenocene Chemical compound [Ru+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 FZHCFNGSGGGXEH-UHFFFAOYSA-N 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012265 solid product Substances 0.000 claims 1
- 150000003303 ruthenium Chemical class 0.000 abstract description 9
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940009456 adriamycin Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 238000004627 transmission electron microscopy Methods 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000002236 cellular spheroid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111053500.8A CN113501848B (zh) | 2021-09-09 | 2021-09-09 | 钌配合物纳米级颗粒及其制备方法和应用以及抗肿瘤药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111053500.8A CN113501848B (zh) | 2021-09-09 | 2021-09-09 | 钌配合物纳米级颗粒及其制备方法和应用以及抗肿瘤药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113501848A true CN113501848A (zh) | 2021-10-15 |
CN113501848B CN113501848B (zh) | 2022-01-14 |
Family
ID=78016803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111053500.8A Expired - Fee Related CN113501848B (zh) | 2021-09-09 | 2021-09-09 | 钌配合物纳米级颗粒及其制备方法和应用以及抗肿瘤药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113501848B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105238814A (zh) * | 2015-09-02 | 2016-01-13 | 广东药学院 | 钌配合物作为靶向细胞核核酸载体的应用 |
-
2021
- 2021-09-09 CN CN202111053500.8A patent/CN113501848B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105238814A (zh) * | 2015-09-02 | 2016-01-13 | 广东药学院 | 钌配合物作为靶向细胞核核酸载体的应用 |
Non-Patent Citations (4)
Title |
---|
LELI ZENG ET AL.: "The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials", 《CHEM. SOC. REV.》 * |
NI WANG ET AL.: "Functionalized Multiwalled Carbon Nanotubes as Carriers of Ruthenium Complexes to Antagonize Cancer Multidrug Resistance and Radioresistance", 《ACS APPL. MATER. INTERFACES》 * |
SABYASACHI CHAKRABORTTY ET AL.: "Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications", 《J. AM. CHEM. SOC.》 * |
YOUNES ELLAHIOUI ET AL.: "Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(II) complex:Exploring the formulation of a metal-based photodynamic therapy photosensitiser", 《DALTON TRANSACTIONS》 * |
Also Published As
Publication number | Publication date |
---|---|
CN113501848B (zh) | 2022-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cai et al. | Nano-sized metal-organic frameworks: Synthesis and applications | |
Wu et al. | Black phosphorus nanosheets-based nanocarriers for enhancing chemotherapy drug sensitiveness via depleting mutant p53 and resistant cancer multimodal therapy | |
Sawy et al. | Insights of doxorubicin loaded graphene quantum dots: Synthesis, DFT drug interactions, and cytotoxicity | |
Djordjevic et al. | Review of synthesis and antioxidant potential of fullerenol nanoparticles | |
Szuplewska et al. | The 10th anniversary of MXenes: Challenges and prospects for their surface modification toward future biotechnological applications | |
Fernandes et al. | Fullerenes for the treatment of cancer: an emerging tool | |
Hashemi et al. | Sonochemically synthesized blue fluorescent functionalized graphene oxide as a drug delivery system | |
Gharehdaghi et al. | Cu (II)-porphyrin metal–organic framework/graphene oxide: synthesis, characterization, and application as a pH-responsive drug carrier for breast cancer treatment | |
Pooresmaeil et al. | D-mannose functionalized MgAl-LDH/Fe-MOF nanocomposite as a new intelligent nanoplatform for MTX and DOX co-drug delivery | |
CN108727353A (zh) | 联合光热治疗和化疗的ir820-ptx两亲性小分子前药及其纳米粒制备方法和应用 | |
Li et al. | Functionalized Graphene Oxide as a nanocarrier of new Copper (II) complexes for targeted therapy on nasopharyngeal carcinoma | |
Pourmadadi et al. | UiO-66 nanoparticles as a drug delivery system: A comprehensive review | |
Iannazzo et al. | Graphene-based materials for application in pharmaceutical nanotechnology | |
Singh et al. | Applications of nanoparticles in various fields | |
WO2010069941A1 (en) | Conjugates comprising nanoparticles coated with platinum containing compounds | |
CN113501848B (zh) | 钌配合物纳米级颗粒及其制备方法和应用以及抗肿瘤药物 | |
Lu et al. | Emerging metallenes: synthesis strategies, biological effects and biomedical applications | |
CN108586551A (zh) | IR780-LA/CPT-ss-CPT纳米粒的制备与应用 | |
Xiao et al. | α-lipoic acid (α-lip) modification on surface of nano-scaled zeolitic imidazole Framework-8 for enhanced drug delivery | |
Abbas et al. | Effect of reaction temperature on shape evolution of palladium nanoparticles and their cytotoxicity against A-549 lung cancer cells | |
WO2020057086A1 (zh) | 一种Fe 3+/2+-NO供体混价配位聚合物及其应用 | |
Fu et al. | Hydrazone modified nanoscale metal-organic frameworks as pH responsive nanoplatforms for cancer therapy | |
Yan et al. | Water-soluble ferrocene complexes (WFCs) functionalized silica nanospheres for WFC delivery in HepG2 tumor therapy | |
Valentini et al. | Graphene as Nanocarrier in Drug Delivery | |
Bieniek et al. | New strategy of controlled, stepwise release from novel MBioF and its potential application for drug delivery systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zeng Leli Inventor after: Li Jia Inventor after: Pan Yihang Inventor after: Zhang Changhua Inventor after: Chao Hui Inventor after: Liao Guolong Inventor after: Fang Shuo Inventor before: Zeng Leli Inventor before: Li Jia Inventor before: Pan Yihang Inventor before: Zhang Changhua Inventor before: Chao Hui Inventor before: Liao Guolong Inventor before: Fang Shuo |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220114 |